Found 18 Enz. Inhib. hit(s) with all data for entry = 3156 TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 3.40E+3nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 8.30E+3nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 8.30E+3nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3 [223-510](Mus musculus (Mouse))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.01E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3 [223-510](Mus musculus (Mouse))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.10E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.38E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.52E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.70E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.75E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3 [223-510](Mus musculus (Mouse))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 1.92E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 2.72E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 4.08E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 4.19E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 1(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 5.38E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 1(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 7.14E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 7.31E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetEyes absent homolog 3(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: 8.11E+4nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 1(Homo sapiens (Human))
Cincinnati Childrens Hospital Medical Center
US Patent
Cincinnati Childrens Hospital Medical Center
US Patent
Affinity DataIC50: >1.50E+5nMAssay Description:The compounds were then tested using full-length human recombinant, purified EYA3 and pNPP as a substrate. Compounds were dissolved in DMSO and dilut...More data for this Ligand-Target Pair
